• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗瘤酮A5的组织培养及动物毒性研究。

Tissue culture and animal toxicity studies of antineoplaston A5.

作者信息

Lee S S, Burzynski S R

出版信息

Drugs Exp Clin Res. 1987;13 Suppl 1:31-5.

PMID:3569013
Abstract

Antineoplaston A5 is a mixture of small to medium size peptides and amino acid derivatives isolated from human urine. This report describes growth inhibition by Antineoplaston A5 of human cell carcinoma line HBL-100 and human leukaemic cell line Jurkat, and acute and chronic toxicity studies in mice. The inhibitory effect of Antineoplaston A5 on HBL-100 cells was tested at concentrations varying from 0.125 mg/ml to 0.5 mg/ml and at exposure durations varying from 24 to 96 h. The tests on Jurkat cells were carried out at concentrations varying from 0.1 mg/ml to 0.8 mg/ml and exposure durations varying from 24 to 120 h. The results from HBL-100 cells, shown as percentage of survival, were as follows: at 0.125 mg/ml 58%; at 0.25 mg/ml 14%; at 0.5 mg/ml 0. Exposure of HBL-100 cells to 0.5 mg/ml of Antineoplaston A5 for 24, 48, 72 and 96 h reduced survival to 55%, 10%, 4% and 0 of the control respectively. The results for suspension culture of Jurkat were as follows: The control cells showed a 7.7-fold increase in cell number during the incubation period, while the cells treated with 0.8 mg/ml of Antineoplaston A5 showed a steady decrease in cell number. At the end of 120 hours' incubation, only 1% of the cells was still viable. The growth inhibition patterns for dosages ranging from 0.4 mg/ml to 0.1 mg/ml were unique; instead of decreasing, the cell numbers in these flasks kept increasing, although at a slower pace during the initial 72 h.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

抗瘤酮A5是从人尿中分离出的中小分子肽和氨基酸衍生物的混合物。本报告描述了抗瘤酮A5对人癌细胞系HBL - 100和人白血病细胞系Jurkat的生长抑制作用,以及在小鼠身上进行的急性和慢性毒性研究。抗瘤酮A5对HBL - 100细胞的抑制作用在浓度为0.125 mg/ml至0.5 mg/ml以及暴露时间为24至96小时的条件下进行测试。对Jurkat细胞的测试在浓度为0.1 mg/ml至0.8 mg/ml以及暴露时间为24至120小时的条件下进行。HBL - 100细胞的结果以存活率百分比表示如下:0.125 mg/ml时为58%;0.25 mg/ml时为14%;0.5 mg/ml时为0。将HBL - 100细胞暴露于0.5 mg/ml的抗瘤酮A5 24、48、72和96小时后,存活率分别降至对照组的55%、10%、4%和0。Jurkat悬浮培养的结果如下:对照细胞在培养期内细胞数量增加了7.7倍,而用0.8 mg/ml抗瘤酮A5处理的细胞数量则稳步下降。在120小时培养结束时,只有1%的细胞仍然存活。浓度范围从0.4 mg/ml到0.1 mg/ml的生长抑制模式独特;这些培养瓶中的细胞数量没有减少,反而持续增加,尽管在最初的72小时内增长速度较慢。(摘要截断于250字)

相似文献

1
Tissue culture and animal toxicity studies of antineoplaston A5.抗瘤酮A5的组织培养及动物毒性研究。
Drugs Exp Clin Res. 1987;13 Suppl 1:31-5.
2
In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3.抗肿瘤物质A3的体外癌症生长抑制及动物毒性研究
Drugs Exp Clin Res. 1987;13 Suppl 1:13-6.
3
Preclinical studies on antineoplaston AS2-1 and antineoplaston AS2-5.抗癌胚肽AS2-1和抗癌胚肽AS2-5的临床前研究。
Drugs Exp Clin Res. 1986;12 Suppl 1:11-6.
4
N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents.N,N'-二取代的L-异谷氨酰胺作为新型癌症化疗药物。
Drugs Exp Clin Res. 1987;13 Suppl 1:57-60.
5
Phase I clinical studies of antineoplaston A5 injections.抗肿瘤蛋白A5注射液的I期临床研究。
Drugs Exp Clin Res. 1987;13 Suppl 1:37-43.
6
Chronic animal toxicity studies on antineoplaston A2.抗瘤氨酸A2的慢性动物毒性研究。
Drugs Exp Clin Res. 1986;12 Suppl 1:73-5.
7
Antineoplastons: history of the research (I).
Drugs Exp Clin Res. 1986;12 Suppl 1:1-9.
8
NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.国家毒理学计划关于水合氯醛(化学物质登记号:302-17-0)毒性和代谢研究的技术报告。通过灌胃法给予F344/N大鼠和B6C3F1小鼠。
Toxic Rep Ser. 1999 Aug(59):1-66, A1-E7.
9
NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.美国国家毒理学计划关于邻苯二甲酸二丁酯(化学物质登记号84 - 74 - 2)经饲料给予F344/N大鼠和B6C3F1小鼠的毒性研究技术报告。
Toxic Rep Ser. 1995 Apr;30:1-G5.
10
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival.
Cancer Res. 1982 Sep;42(9):3532-7.

引用本文的文献

1
Potential of antineoplastons in diseases of old age.
Drugs Aging. 1995 Sep;7(3):157-67. doi: 10.2165/00002512-199507030-00001.